Contrast-Enhanced Transrectal Ultrasound in Focal Therapy for Prostate Cancer

Purpose of Review Contrast-enhanced transrectal ultrasound (CeTRUS) is an emerging imaging technique in prostate cancer (PCa) diagnosis and treatment. We review the utility and implications of CeTRUS in PCa focal therapy (FT). Recent Findings CeTRUS utilizes intravenous injection of ultrasound-enhan...

Full description

Saved in:
Bibliographic Details
Published in:Current urology reports 2018-10, Vol.19 (10), p.87-87, Article 87
Main Authors: Ashrafi, Akbar N., Nassiri, Nima, Gill, Inderbir S., Gulati, Mittul, Park, Daniel, de Castro Abreu, Andre L.
Format: Article
Language:English
Subjects:
Contrast Media - pharmacology
Endosonography - methods
Humans
Male
Medicine
Medicine & Public Health
Nephrology
New Imaging Techniques (S Rais-Bahrami and K Porter
Prostate - diagnostic imaging
Prostate - surgery
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - therapy
Rectum
Section Editors
Topical Collection on New Imaging Techniques
Ultrasound, High-Intensity Focused, Transrectal - methods
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review Contrast-enhanced transrectal ultrasound (CeTRUS) is an emerging imaging technique in prostate cancer (PCa) diagnosis and treatment. We review the utility and implications of CeTRUS in PCa focal therapy (FT). Recent Findings CeTRUS utilizes intravenous injection of ultrasound-enhancing agents followed by high-resolution ultrasound to evaluate tissue microvasculature and differentiate between benign tissue and PCa, with the latter demonstrating increased enhancement. The potential utility of CeTRUS in FT for PCa extends to pre-, intra- and post-operative settings. CeTRUS may detect PCa, facilitate targeted biopsy and aid surgical planning prior to FT. During FT, the treated area can be visualized as a well-demarcated non-enhancing zone and continuous real-time assessment allows immediate re-treatment if necessary. Following FT, the changes on CeTRUS are immediate and consistent, thus facilitating repeat imaging for comparison during follow-up. Areas suspicious for recurrence may be detected and target-biopsied. Enhancement can be quantified using time-intensity curves allowing objective assessment and comparison. Summary Based on encouraging early outcomes, CeTRUS may become an alternative imaging modality in prostate cancer FT. Further study with larger cohorts and longer follow-up are needed.
ISSN:1527-2737
1534-6285
1534-6285
DOI:10.1007/s11934-018-0836-6